Why Strain Specificity Matters
When a clinical trial shows that a probiotic works for IBS, it shows that a specific strain works — for example, Bifidobacterium infantis 35624. The evidence does not transfer to other Bifidobacterium strains, let alone to a random 10-strain blend that may not contain that strain at all. Probiotics are not medicines with a single active ingredient and universal mechanism. Each strain has distinct colonization patterns, metabolic outputs, immune signaling properties, and clinical evidence profiles.
The consumer-facing probiotic market has systematically obscured this fact by competing on CFU counts — a number that sounds meaningful and is easy to compare but says almost nothing about clinical efficacy. A well-studied strain at 1 billion CFU frequently outperforms an unstudied strain at 100 billion CFU for any specific health goal. This is not an edge case — it is how probiotic science works.
For an overview of which probiotics have the broadest evidence base, see our probiotic scorecard.
Lactobacillus Strains
Lactobacillus species dominate the small intestine and vagina. They produce lactic acid and hydrogen peroxide, which create an acidic, protective microenvironmental niche. Most Lactobacillus-based probiotic evidence clusters around gut health, vaginal microbiome support, and antibiotic-associated diarrhea prevention.
L. rhamnosus GG (LGG)
The most clinically studied probiotic strain in existence. LGG has accumulated evidence across hundreds of randomized controlled trials. Its strongest evidence is for antibiotic-associated diarrhea (AAD) prevention: a 2019 Cochrane meta-analysis found that LGG significantly reduced the risk of AAD in children and adults taking antibiotics. It also has evidence for reducing the duration of acute diarrhea in children and modest support for reducing recurrence of C. difficile infection alongside antibiotic treatment.
LGG is commercially available in Culturelle products. The standard evidence-based dose is 10 billion CFU twice daily when used during antibiotic treatment.
L. acidophilus NCFM
One of the most commonly included strains in multi-strain products. L. acidophilus NCFM has randomized trial evidence for reducing symptoms of lactose intolerance and immune modulation — specifically reducing the frequency and duration of cold episodes. It also appears in vaginal health studies, though the GR-1/RC-14 combination (see below) has stronger strain-specific evidence for that use case.
L. plantarum 299v
L. plantarum 299v has the best Lactobacillus evidence for IBS symptom reduction, particularly abdominal pain and bloating. A 2012 randomized trial in World Journal of Gastroenterology found significant symptom improvement versus placebo over 4 weeks. The mechanism is thought to involve gut barrier reinforcement and reduction of visceral hypersensitivity. Available in Jarrow Ideal Bowel Support.
L. reuteri (DSM 17938 and ATCC PTA 6475)
L. reuteri has evidence in two distinct use cases. DSM 17938 is the most studied strain for infant colic, with a Cochrane-level meta-analysis showing significant reduction in daily crying time compared to placebo or simethicone. The ATCC PTA 6475 strain has clinical evidence for H. pylori adjunctive therapy and modest data on bone density in men (a research-stage finding, not a settled clinical claim).
L. rhamnosus GR-1 + L. reuteri RC-14 (vaginal health)
This strain pair has the strongest evidence base for vaginal microbiome support. A foundational study by Reid and colleagues (2003) demonstrated that oral supplementation with GR-1 and RC-14 successfully colonized the vagina and reduced vaginal abnormalities in women with recurrent bacterial vaginosis. Subsequent trials have confirmed the strain combination's ability to restore normal Lactobacillus-dominant vaginal flora when taken orally. Available in RepHresh Pro-B and Jarrow Fem-Dophilus.
Bifidobacterium Strains
Bifidobacterium species colonize the large intestine and are particularly important for early life microbiome development and gut-immune interaction. They ferment dietary fibers and produce short-chain fatty acids (SCFAs) that feed the colonic epithelium.
B. infantis 35624 (IBS)
The most evidence-backed Bifidobacterium strain for irritable bowel syndrome. A 2006 randomized controlled trial by Whorwell and colleagues in the American Journal of Gastroenterology enrolled 362 IBS patients and found that 1 billion CFU of B. infantis 35624 significantly reduced IBS symptom composite scores compared to placebo, including improvements in abdominal pain, bloating, bowel dysfunction, and quality of life. This is one of the cleaner IBS probiotic trials in the literature. Available in Align (Procter & Gamble).
B. longum 1714
An emerging strain with small but interesting trial data for psychological stress. A 2019 randomized trial found that B. longum 1714 reduced subjective stress and improved memory performance in healthy volunteers over 4 weeks compared to placebo. This reflects growing interest in the gut-brain axis, where specific Bifidobacterium strains appear to modulate HPA axis activity and stress hormone levels. The clinical evidence base is early-stage; this is a watch-this-space finding rather than a settled efficacy claim.
B. lactis (multiple strains)
Several B. lactis strains — particularly BB-12, Bi-07, and HN019 — have evidence for bowel regularity and immune modulation. BB-12 has among the most clinical trial data of any Bifidobacterium strain and appears across studies of antibiotic-associated diarrhea, infant health, and reducing upper respiratory tract infection frequency. HN019 has specific evidence for transit time and constipation relief. B. lactis strains appear in Align 24/7, Garden of Life products, and Florastor Kids.
Saccharomyces boulardii (Yeast-Based Probiotic)
S. boulardii is not a bacterium — it is a yeast, making it structurally distinct from all Lactobacillus and Bifidobacterium products and resistant to antibiotics. This is its primary practical advantage: it can be taken simultaneously with antibiotics without being killed.
Its strongest evidence is for antibiotic-associated diarrhea prevention, comparable to LGG in terms of effect size. A 2020 Cochrane meta-analysis by Guo and colleagues found that S. boulardii significantly reduced AAD risk (RR 0.47, 95% CI 0.38–0.57) across 21 trials. It also has evidence for traveler's diarrhea prevention and is the only probiotic with trial data supporting adjunctive use in C. difficile recurrence prevention.
Available in Florastor (the original pharmaceutical preparation) and in many generic formulations. Standard dose: 250–500 mg twice daily, starting at the beginning of antibiotic treatment.
Bacillus (Spore-Forming) Probiotics
Bacillus coagulans and Bacillus subtilis are spore-forming bacteria with dramatically superior shelf stability compared to Lactobacillus or Bifidobacterium. The spore structure protects the organism through stomach acid, and the products do not require refrigeration. This makes them popular in shelf-stable consumer products and protein powders with added probiotics.
The trade-off: the clinical evidence base for Bacillus strains is substantially smaller than for LGG, B. infantis 35624, or S. boulardii. B. coagulans GBI-30, 6086 (marketed as GanedenBC30) has IBS and bowel symptom data, and B. subtilis DE111 has some immune data. These are promising but not the strains to reach for when treating a specific condition with evidence-backed options available.
Evidence Summary by Condition
Antibiotic-associated diarrhea
Best-evidence strains: L. rhamnosus GG and S. boulardii, both with Cochrane-level meta-analysis support. These are the only probiotics where the evidence is strong enough to consider routine prevention during antibiotic courses. Start at the same time as the antibiotic. Continue for 1–2 weeks after the course ends.
IBS
Best-evidence strains: B. infantis 35624 (Align) for global IBS symptom reduction; L. plantarum 299v for abdominal pain and bloating specifically. A broader 2014 meta-analysis by Ford and colleagues in the American Journal of Gastroenterology found that probiotics as a class reduced IBS symptoms versus placebo, but noted significant heterogeneity across studies — again reflecting the strain-specificity problem. Single-strain products with published clinical data outperform generic multi-strain blends for IBS. See our best probiotic for IBS picks.
Vaginal health
Best-evidence combination: L. rhamnosus GR-1 + L. reuteri RC-14, taken orally. Evidence for restoring Lactobacillus-dominant vaginal flora and reducing recurrent bacterial vaginosis. Available in Jarrow Fem-Dophilus and RepHresh Pro-B. Standard dose: 1 capsule daily providing both strains. This is a maintenance strategy, not an acute treatment — acute BV requires antibiotic treatment.
Immune support
This is the weakest area for strain-specific claims. Multiple strains have shown modest reductions in cold duration or upper respiratory infection frequency in RCTs — including LGG, B. lactis BB-12, and L. acidophilus NCFM — but the effect sizes are small and the practical significance is debatable. Probiotic immune support is probably best understood as a downstream benefit of general microbiome health maintenance rather than a targeted intervention.
How to Read a Probiotic Label
When evaluating a probiotic product, look for four things in order of importance:
- Strain designation, not just genus and species. "Lactobacillus acidophilus" tells you almost nothing. "Lactobacillus acidophilus NCFM" tells you the specific strain with a clinical data trail. Products that list only genus and species without strain identifiers cannot be matched to any published clinical evidence.
- CFU count at the end of shelf life, not at manufacture. Many products are manufactured with higher CFU counts because organisms die over time. A product claiming "10 billion CFU" should specify whether that count is guaranteed at the expiration date or only at manufacture. End-of-shelf-life guarantees are what matters.
- Delivery mechanism. Does the product protect organisms through stomach acid? Enteric coating, delayed-release capsules, or spore form (for Bacillus strains) are meaningful. Organisms that die in stomach acid before reaching the small intestine provide little benefit regardless of CFU count.
- Storage requirements. Lactobacillus and Bifidobacterium products typically require refrigeration after opening unless specifically formulated for shelf stability. Bacillus and S. boulardii products are shelf-stable.
See our best probiotic supplements ranking for products we have evaluated on all four criteria.
FAQ
Can you take multiple probiotic strains at once?
Yes, and multi-strain products are common. The concern about strains competing is generally overstated — different strains colonize different niches and are not necessarily in direct competition. The practical issue with multi-strain blends is that each strain is present at a lower CFU count, potentially falling below the effective dose studied in clinical trials. If you have a specific condition with evidence for a particular strain, a single-strain or targeted product may be more reliable than a large multi-strain blend where each strain may be pixie-dusted.
How long should you take a probiotic?
Depends on the goal. For antibiotic-associated diarrhea prevention: start at the same time as the antibiotic and continue 1–2 weeks after finishing. For IBS: clinical trials typically run 4–8 weeks; ongoing use for maintenance is common if benefit is observed. For vaginal health: ongoing daily use is the standard protocol in the clinical literature. Probiotics do not permanently colonize the gut — most strains are transient colonizers that require continuous supplementation to maintain their effect.
Does refrigeration matter?
Yes for most Lactobacillus and Bifidobacterium products. These organisms lose viability at room temperature over time, and the expiration date assumes proper cold-chain storage. A probiotic left at room temperature for extended periods may contain far fewer viable organisms than labeled. Bacillus (spore-forming) and S. boulardii products are shelf-stable exceptions.
Are probiotics safe?
For healthy adults, yes — they are among the safest supplement categories with a very low adverse event rate in clinical trials across decades of research. The primary exceptions: people with severely compromised immune systems, critical illness, or central line catheters have rare but documented cases of probiotic-associated bacteremia or fungemia. Standard consumer probiotic use carries no meaningful risk for healthy people. Severe immunocompromised individuals should consult their physician before starting any probiotic.
Sources
- Whorwell PJ, Altringer L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. PubMed
- Reid G, Charbonneau D, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35(2):131-4. PubMed
- Guo Q, Goldenberg JZ, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. PubMed
- Ford AC, Quigley EM, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-61. PubMed
These statements have not been evaluated by the FDA. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.